Johnson & Johnson
Johnson and Johnson Innovation, Jpal
Janssen Inc.
Director, Clinical Project Scientist, Oncology
Bind Therapeutics 2014 - 2016
Senior Director, Clinical
Bind Therapeutics 2013 - 2014
Director, Clinical
Bind Therapeutics 2011 - 2013
Head of Clinical Operations and Program Manager For Bind-014
Education:
Boston University 2007 - 2010
Master of Business Administration, Masters, Management
Penn State University Sep 1995 - 1999
Bachelors, Bachelor of Science, Chemistry
Skills:
Clinical Trials Biotechnology Clinical Development Drug Development Oncology Clinical Research Life Sciences Fda Pharmaceutical Industry Gcp Project Management Regulatory Submissions Ind Clinical Operations Drug Discovery Cross Functional Team Leadership Chromatography Ctms Gmp Program Management Strategic Planning Good Clinical Practice Clinical Trial Management System U.s. Food and Drug Administration Cmc Pre Clinical Studies Phase 1 Phase 2
Certifications:
Certification In Applied Project Management Biotechnology Project Management Boston University Massachusetts Biotechnology Council
Richard P. Batycky - Newton MA, US Giovanni Caponetti - Piacenza, IT Mariko Childs - Arlington MA, US Elliot Ehrich - Lincoln MA, US Karen Fu - Cambridge MA, US Jeffrey S. Hrkach - Cambridge MA, US Wen-I Li - Lexington MA, US Michael M. Lipp - Framingham MA, US Mei-Ling Pan - Cambridge MA, US Jason Summa - Arlington MA, US
Assignee:
Civitas Therapeutics, Inc. - Chelsea MA
International Classification:
A61K 9/14 A61K 31/13 A61K 31/135 A61K 31/045
US Classification:
514653, 514669, 514728, 424 46, 424489
Abstract:
The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
Richard Batycky - Newton MA, US Giovanni Caponetti - Piacenza, IT Mariko Childs - Arlington MA, US Elliot Ehrich - Lincoln MA, US Karen Fu - Cambridge MA, US Jeffrey Hrkach - Cambridge MA, US Wen-I Li - Lexington MA, US Michael Lipp - Framingham MA, US Mei-Ling Pan - Cambridge MA, US Jason Summa - Arlington MA, US
International Classification:
A61L009/04 A61K009/14 A61K031/137
US Classification:
424/046000, 514/649000
Abstract:
The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
Giovanni Caponetti - Piacenza, IT Mariko Childs - Arlington MA, US Elliot Ehrich - Lincoln MA, US Karen Fu - Lexington MA, US Jeffrey S. Hrkach - Lexington MA, US Wen-I Li - Lexington MA, US Michael M. Lipp - Framingham MA, US Mei-Ling Pan - Cambridge MA, US Jason Summa - Cambridge MA, US
Assignee:
Civitas Therapeutics, Inc. - Chelsea MA
International Classification:
A61K 9/00 A61K 31/137
US Classification:
514653
Abstract:
The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
Methods Of Treating Cancers With Therapeutic Nanoparticles
The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.
- Chelsea MA, US Giovanni Caponetti - Piacenza, IT Mariko Childs - Arlington MA, US Elliot Ehrich - Boston MA, US Karen Fu - Lexington MA, US Jeffrey S. Hrkach - Lexington MA, US Wen-I Li - Lexington MA, US Michael M. Lipp - Framingham MA, US Mei-Ling Pan - Cambridge MA, US Jason Summa - Cambridge MA, US
International Classification:
A61K 31/137 A61M 15/00 A61K 9/00
Abstract:
The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
Nanoparticles Comprising Docetaxel For Treating Cancers Having A K-Ras Mutation
The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.
- Chelsea MA, US Giovanni Caponetti - Piacenza, IT Mariko Childs - Arlington MA, US Elliot Ehrich - Lincoln MA, US Karen Fu - Lexington MA, US Jeffrey S. Hrkach - Lexington MA, US Wen-I Li - Lexington MA, US Michael M. Lipp - Framingham MA, US Mei-Ling Pan - Cambridge MA, US Jason Summa - Cambridge MA, US
Assignee:
Civitas Therapeutics, Inc. - Chelsea MA
International Classification:
A61K 31/137 A61K 9/00
US Classification:
514653
Abstract:
The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.